Bexagliflozin

Active ingredient: Bexagliflozin

In short: Bexagliflozin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use Bexagliflozin is not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus.

Forms & strengthsTablets: 20 mg, blue, caplet-shaped, biconvex, bevel-edged, debossed with “2” and inverted “2” on one side.
LabelGolden State Medical Supply, Inc.
Label updatedAug 28, 2026

What is Bexagliflozin used for?

Bexagliflozin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Limitations of Use

Bexagliflozin is not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus.

.

Bexagliflozin dosage

• Assess renal function prior to initiation of bexagliflozin tablets and periodically thereafter as clinically indicated

. Bexagliflozin is not recommended in patients with an eGFR less than 30 mL/min/1.73 m

2

• Assess volume status. In patients with volume depletion, correct this condition before initiating bexagliflozin tablets

.

• The recommended dosage of bexagliflozin tabletsis 20 mg orally taken once daily in the morning, with or without food

.

• Do not crush or chew the tablet.

• Withhold bexagliflozin tablets for at least 3 days, if possible, prior to surgery or procedures associated with prolonged fasting. Resume bexagliflozin tablets when the patient is clinically stable and has resumed oral intake

.

If a dose is missed, instruct patients to take the dose as soon as possible.

Advise patients not to double up the next dose.

How to take Bexagliflozin — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Medication Guide).

Diabetic Ketoacidosis in Patients with Type 1 Diabetes Mellitus and Other Ketoacidosis

Inform patients that bexagliflozin tablets can cause potentially fatal ketoacidosis and that type 2 diabetes mellitus and pancreatic disorders (e.g., history of pancreatitis or pancreatic surgery) are risk factors.

Educate all patients on precipitating factors (such as insulin dose reduction or missed insulin doses, infection, reduced caloric intake, ketogenic diet, surgery, dehydration, and alcohol abuse) and symptoms of ketoacidosis (including nausea, vomiting, abdominal pain, tiredness, and labored breathing). Inform patients that blood glucose may be normal even in the presence of ketoacidosis.

Advise patients that they may be asked to monitor ketones. If symptoms of ketoacidosis occur, instruct patients to discontinue bexagliflozin tablets and seek medical attention immediately

.

Lower Limb Amputation

Inform patients of the potential for an increased risk of amputations with bexagliflozin tablets. Counsel patients on the importance of routine preventive foot care. …

Warnings & precautions

Do not take this medicine if: Bexagliflozin tablets are contraindicated in patients:

With hypersensitivity to bexagliflozin or any excipient in bexagliflozin tablets. Anaphylaxis and angioedema have been reported with sodium-glucose co-transporter 2 (SGLT2) inhibitors.

In patients with type 1 diabetes mellitus, bexagliflozin tablets significantly increase the risk of diabetic ketoacidosis, a life-threatening event, beyond background rate. In placebo-controlled trials of patients with type 1 diabetes mellitus, the risk of ketoacidosis was markedly increased in patients who received sodium glucose transporter 2 (SGLT2) inhibitors compared to patients who received placebo. Bexagliflozin tablets are not indicated for glycemic control in patients with type 1 diabetes mellitus.

Type 2 diabetes mellitus and pancreatic disorders (e.g., history of pancreatitis or pancreatic surgery) are also risk factors for ketoacidosis. There have been postmarketing reports of fatal events of ketoacidosis in patients with type 2 diabetes mellitus using SGLT2 inhibitors.

Precipitating conditions for diabetic ketoacidosis or other ketoacidosis include under-insulinization due to insulin dose reduction or missed insulin doses, acute febrile illness, reduced caloric intake, ketogenic diet, surgery, volume depletion, and alcohol abuse.

Signs and symptoms are consistent with dehydration and severe metabolic acidosis and include nausea, vomiting, abdominal pain, generalized malaise, and shortness of breath. Blood glucose levels at presentation may be below those typically expected for diabetic ketoacidosis (e.g., less than 250 mg/dL). Ketoacidosis and glucosuria may persist longer than typically expected. …

Bexagliflozin side effects

The following important adverse reactions are described below and elsewhere in the labeling:

Diabetic Ketoacidosis in Patients with Type 1 Diabetes Mellitus and Other Ketoacidosis

Lower Limb Amputation

Volume Depletion

Genitourinary Infections, including Urosepsis, Pyelonephritis, Necrotizing Fasciitis of the Perineum (Fournier’s Gangrene), and Genital Mycotic Infections

Hypoglycemia with Concomitant Use with Insulin and Insulin Secretagogues

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Pool of Placebo-Controlled Trials Evaluating Bexagliflozin

Tablets, 20 mg

The data in

Table 1 are derived from three trials in adults with type 2 diabetes mellitus: two 24-week placebo-controlled trials (one as monotherapy and another as add-on to metformin therapy; Trials 1 and 2, respectively)

and a 12-week, placebo-controlled, dose-ranging, monotherapy trial (only the data from the 20 mg dosage of bexagliflozin tablets per day were included in this pool). In these pooled trials, patients received placebo (N = 300) or bexagliflozin 20 mg (N = 372), once daily. The mean age of the population was 56 years and 5% of the patients were older than 75 years of age. Fifty-seven percent (57%) were male and 45% were White, 38% Asian, 15% Black and 2% other races. …

Drug interactions

See

Table 4 for clinically significant interactions with bexagliflozin tablets.

Table 4. Clinically Significant Interactions with Bexagliflozin Tablets

UGT Enzyme Inducers

Clinical Impact | UGT Enzyme Inducers may significantly reduce exposure to bexagliflozin and lead to a decreased efficacy .

Intervention | Consider adding another antihyperglycemic agent in patients who require additional glycemic control.

Concomitant Use with Insulin and Insulin Secretagogues

Clinical Impact | The risk of hypoglycemia is increased when bexagliflozin tablets are used in combination with insulin and/or an insulin secretagogue.

Intervention | A lower dose of insulin or insulin secretagogue may be required to minimize the risk of hypoglycemia when used in combination with bexagliflozin tablets.

Lithium

Clinical Impact | Concomitant use with SGLT2 inhibitors such as bexagliflozin tablets may decrease serum lithium concentrations.

Intervention | Monitor serum lithium concentration more frequently upon bexagliflozin tablets initiation and discontinuation.

Positive Urine Glucose Test

Clinical Impact | SGLT2 inhibitors increase urinary glucose excretion and will lead to positive urine glucose tests. …

About this medicine

Bexagliflozin tablets for oral use contain bexagliflozin, an SGLT2 inhibitor.

The chemical name of bexagliflozin is (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-(2-cyclopropoxyethoxy)benzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol.

The molecular formula is C

24H

29ClO

7and the molecular weight is 464.94 g/mol. The structural formula is:

Bexagliflozin is a white/off-white to pale yellow powder. It is very slightly soluble in water and freely soluble in methanol, acetone, ethylene glycol, and propylene glycol. It is slightly soluble in heptane, cyclohexane, and toluene. Crystalline bexagliflozin is not hygroscopic.

Each film-coated tablet contains 20 mg of bexagliflozin and the inactive ingredients colloidal silicon dioxide, glyceryl dibehenate, lactose monohydrate, magnesium stearate, microcrystalline cellulose, polyethylene oxide, and poloxamer 188. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 1a3ba9d5-1009-bad0-e063-6294a90ac4cc. Read the full official label on DailyMed.

Related medicines

Atorvastatin Metformin Losartan Semaglutide Insulin Glargine Empagliflozin Glipizide Insulin Lispro